Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events.
Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based …

Spondyloarthritis (SpA) comprises a group of chronic inflammatory diseases with
overlapping clinical, genetic and pathophysiological features including back pain, peripheral …

Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …

Objective JAK inhibitor therapies are effective treatment options for immune‐mediated
inflammatory diseases (IMIDs), but their use has been limited by venous thromboembolism …

Objective To evaluate the risk of common infections in individuals with inflammatory bowel
disease (IBD)[ulcerative colitis and Crohn's disease] compared with matched controls in a …

Objectives To provide an integrated analysis of major adverse cardiovascular events
(MACEs) and events of venous thromboembolism (VTE) and associated risk factors across …

Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …

Background Inflammatory bowel disease (IBD) has a significant impact on quality of life for
many people. Objective To assess the prevalence of common mental health conditions in …

OBJECTIVE: Rheumatoid arthritis (RA) patients are prone to develop thromboembolic
complications due to the chronic inflammatory nature of RA. Only one systematic review and …

Many epidemiological studies have shown an increased risk of venous thromboembolism
(VTE) in patients with rheumatoid arthritis (RA). RA and VTE share some background …